Addex Therapeutics Announces H1 and Q2 2024 Financial Outcomes Along with Organizational Progress

Addex Therapeutics Ltd ADXN, a pioneering biopharmaceutical enterprise focusing on the discovery, development, and commercialization of small molecule drug candidates for central nervous system (CNS) disorders, recently released its financial results for the first half and second quarter of 2024. These reports delineate the company's financial health and provide insights into its corporate evolution.

2024 Half-Year and Q2 Financial Overview

ADXN has presented an ad hoc announcement pursuant to Art. 53 LR, articulating the financial figures and corporate maneuvers during the initial half and second quarter of the year. The disclosure highlights noteworthy financial metrics, including revenue generation, operational expenses, and net profit or loss figures. The report is a comprehensive account, essential for investors and market analysts to assess the company's financial trajectory and strategic decisions.

Corporate Developments and Strategic Updates

Alongside the financial data, ADXN has also provided a corporate update detailing the advancements in its pharmaceutical pipeline, recent market activities, and strategic initiatives aimed at fostering growth and creating shareholder value. These updates are integral for keeping the investors and stakeholders abreast of the company's ongoing and future projects.

About Indivior PLC and Addex Therapeutics

Indivior PLC INDV, operates in the pharmaceutical sector, producing buprenorphine-based medications catered towards the treatment of opioid dependence. Located in North Chesterfield, Virginia, INDV sustains a dedicated focus on addressing the challenges of opioid addiction and associated disorders.

Conversely, ADXN, based in Geneva, Switzerland, emphasizes the development of novel pharmaceutical solutions for central nervous system disorders, an area of high unmet medical need. The company embraces innovative research and development practices with the aim of bringing transformative treatments to market.

Addex, Indivior, Financial